Article: Changes in NMN/NAD+ Ratio Activates SARM1 to Trigger Nerve Damage: Preclinical Findings

PrevNext
Neurological Health Neuropathy Preclinical

Changes in NMN/NAD+ Ratio Activates SARM1 to Trigger Nerve Damage: Preclinical Findings

Synopsis

Axon degeneration is a key feature of many neurodegenerative diseases. SARM1 is an enzyme that breaks down NAD+ and, when activated, causes axon destruction. The enzyme NMNAT2 normally converts NMN to NAD+, but when NMNAT2 is lost, SARM1 is activated by an increased ratio of NMN to NAD+. Both NMN and NAD+ bind to the same part of SARM1, competing with each other. Structural studies show how NMN binding changes SARM1's shape, and mutating the binding site stops SARM1 activation and axon damage after injury. Thus, SARM1 acts as a metabolic sensor detecting high NMN/NAD+ ratios, triggering NAD+ breakdown and leading to axon degeneration.

Journal

Neuron

Share

Read more

Metabolic Health

Combination of Metabolic Cofactors and Nicotinamide Riboside Reduces Obesity and Insulin Resistance: Preclinical Findings

SynopsisObesity is a global health problem marked by excessive fat that often leads to metabolic issues like insulin resistance, high blood pressure, abnormal cholesterol levels, and metabolic synd...

Read more
Healthy Aging & Longevity

Cockayne Syndrome Proteins Maintain Mitochondrial Health Through NAD+ Signaling: Preclinical Findings

SynopsisCockayne syndrome (CS) is a rare premature aging disorder involving DNA repair defects and mitochondrial dysfunction. Across human, mouse, and nematode models, mitochondrial dysfunction was...

Read more